1. Home
  2. SKYE

as of 12-02-2025 4:00pm EST

$1.11
$0.10
-8.26%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Chart Type:
Time Range:
Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 44.9M IPO Year: N/A
Target Price: $14.75 AVG Volume (30 days): 285.3K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.29 EPS Growth: N/A
52 Week Low/High: $1.11 - $5.75 Next Earning Date: 11-10-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered SKYE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 79.58%
79.58%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: